Pfizer (PFE) Income from Continuing Operations (2009 - 2026)

Pfizer (PFE) has reported Income from Continuing Operations for 18 consecutive years, with -$246.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 108.47% year-over-year to -$246.0 million in Q2 2026; TTM through Jun 2026 was $4.4 billion, a 67.72% decrease from a year earlier, with the FY2025 full-year figure at $7.8 billion, down 3.29% from the prior year.
• Income from Continuing Operations was -$246.0 million for Q2 2026 at Pfizer, down from $2.7 billion in the prior quarter.
• Over five years, Income from Continuing Operations peaked at $9.9 billion in Q3 2022 and troughed at -$3.3 billion in Q4 2023.
• A 5-year average of $3.1 billion and a median of $2.9 billion in 2025 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations surged 9264.52% in 2025 and sank 108.47% in 2026, its largest moves.
• Over 5 years, Income from Continuing Operations stood at $9.9 billion in 2022, then plunged by 133.76% to -$3.3 billion in 2023, then jumped by 329.15% to $7.6 billion in 2024, then plunged by 121.47% to -$1.6 billion in 2025, then jumped by 85.0% to -$246.0 million in 2026.
• The last three Income from Continuing Operations figures came in at -$246.0 million (Q2 2026), $2.7 billion (Q1 2026), and -$1.6 billion (Q4 2025), per Business Quant data.